Decrease in serum lipids, glycemia and body weight by Plantago psyllium in obese and diabetic patients
The GHK-Cu Optimal Balance Pharmacy compounds is a sterile injectable intended for subcutaneous administration
The nutrients that trigger GLP-1 secretion are macronutrients simple sugars (monosaccharides), peptides and amino acids (from proteins), and short chain fatty acids (from fats and also produced by good gut bacteria)
J Clin Endocrinol Metab 100(8):29092917
Retatrutide is an investigational triple agonist targeting GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-dependent Insulinotropic Polypeptide) and glucagon receptors, studied in the phase 2 obesity trial published in 2023 and now progressing through the Phase 3 TRIUMPH programme
Injectable GHK-Cu is not an FDA-approved drug, and products sold for this purpose are typically labeled "for research purposes only," meaning they are not intended for human therapeutic use